Post on 15-Jul-2015
transcript
The ColaLife panel contributionConsultation on transforming healthcare deliveryANDi, Addis Ababa, January 2015 Simon Berry
ColaLife is a charity registered in the UKCharity number: 1142516
• Small, independent and catalytic• Focus on saving children’s lives• Looking for global impact through
• Innovation• Generating robust evidence• Sharing findings and learning• Influencing healthcare strategies
• No commercial interest
2009 2010 2011 2012 20131985What is ColaLife and who am I?
The scope of our work
What happened
Our starting point
2
4
The effects
5
1
The ColaLife contribution
Consultation on transforming healthcare delivery
ANDi, Addis Ababa, January 2015
Recommendations
6
What we did
3
The scope of our work
What happened
Our starting point
The effects
1
The ColaLife contribution
Consultation on transforming healthcare delivery
ANDi, Addis Ababa, January 2015
Recommendations
What we did
2 3
4 5 6
The scope of our work
What happened
Our starting point
The effects
The ColaLife contribution
Consultation on transforming healthcare delivery
ANDi, Addis Ababa, January 2015
Recommendations
What we did
2 3
4 5 6
1
The scope of our work
What happened
Our starting point
The effects
The ColaLife contribution
Consultation on transforming healthcare delivery
ANDi, Addis Ababa, January 2015
Recommendations
What we did
2 3
4 5 6
1
Mimicking Coca-Cola – creating a product people WANT
What we learnt
Litre sachets are too big
Measuring water was an issue
Willingness to pay
Preferred branding
3
Kit Yamoyo• Attractive
• Affordable
• Packaging is also:
• A measuring device for
the water
• A mixing device
• A storage device (the
soap tray is a lid)
• A cup
• And can be re-used
3
The scope of our work
What happened
Our starting point
The effects
The ColaLife contribution
Consultation on transforming healthcare delivery
ANDi, Addis Ababa, January 2015
Recommendations
What we did
2 3
4 5 6
1
Distribution
WholesaleK3.10
RetailK3.70
CustomerK5.00
4
Demand PULLED the Kit Yamoyo into rural communities
Assembly
Distribution
WholesaleK3.10
RetailK3.70
CustomerK5.00
4
Demand PULLED the Kit Yamoyo into rural communities
Manufacture
Assembly
Distribution
WholesaleK3.10
RetailK3.70
CustomerK5.00
4
Demand PULLED the Kit Yamoyo into rural communities
Manufacture
Assembly
Distribution
WholesaleK3.10
RetailK3.70
CustomerK5.00
4
Demand PULLED the Kit Yamoyo into rural communities
Manufacture
Assembly
Distribution
WholesaleK3.10
RetailK3.70
CustomerK5.00
4
Demand PULLED the Kit Yamoyo into rural communities
The scope of our work
What happened
Our starting point
The effects
The ColaLife contribution
Consultation on transforming healthcare delivery
ANDi, Addis Ababa, January 2015
Recommendations
What we did
2 3
4 5 6
1
0Nobody sold ORS or Zinc in the private sector.
Stock-outs in the public sector were common.
<1%of children received the correct treatment for diarrhoea
0Nobody sold ORS or Zinc in the private sector.
Stock-outs in the public sector were common.
<1%of children received the correct treatment for diarrhoea
7.3kmWas the average distance to ORS.
60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.
0Nobody sold ORS or Zinc in the private sector.
Stock-outs in the public sector were common.
<1%of children received the correct treatment for diarrhoea
7.3kmWas the average distance to ORS.
60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.
0Nobody sold ORS or Zinc in the private sector.
Stock-outs in the public sector were common.
<1%of children received the correct treatment for diarrhoea
7.3kmWas the average distance to ORS.
60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.
0Nobody sold ORS or Zinc in the private sector.
Stock-outs in the public sector were common.
<1%of children received the correct treatment for diarrhoea
7.3kmWas the average distance to ORS.
>26kkits sold into the two remote rural trial areas in 12 months.
60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.
0Nobody sold ORS or Zinc in the private sector.
Stock-outs in the public sector were common.
<1%of children received the correct treatment for diarrhoea
7.3kmWas the average distance to ORS.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.
0Nobody sold ORS or Zinc in the private sector.
Stock-outs in the public sector were common.
<1%of children received the correct treatment for diarrhoea
7.3kmWas the average distance to ORS.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.
0Nobody sold ORS or Zinc in the private sector.
Stock-outs in the public sector were common.
<1%of children received the correct treatment for diarrhoea
7.3kmWas the average distance to ORS.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.
60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.
0Nobody sold ORS or Zinc in the private sector.
Stock-outs in the public sector were common.
<1%of children received the correct treatment for diarrhoea
7.3kmWas the average distance to ORS.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.
The scope of our work
What happened
Our starting point
The effects
The ColaLife contribution
Consultation on transforming healthcare delivery
ANDi, Addis Ababa, January 2015
Recommendations
What we did
2 3
4 5 6
1
6
Don’t ignore EXISTING private sector supply chains in your strategy to distribute over the counter medicines
Under-5 children have died from dehydration caused by diarrhoeain the time it took to give this presentation